All In Biotech

Drug Trial Radar · NCT02066402

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

A Phase 3 Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate and Intravenous to Oral 10-Day Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections

Last checked: Nov 20, 2026Latest source record: Jun 7, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 598 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

598

Actual

Start

Mar 4, 2014

Primary completion

Mar 6, 2016

Study completion Apr 18, 2016

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Feb 19, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is aimed to evaluate the efficacy and safety between Tedizolid 200mg daily (intra venous) I.V. to oral for 6-day treatment compared with that of Linezolid 600mg twice daily I.V. to oral for 10-day treatment Acute Bacterial Skin and skin structure infection (ABSSSI).This is a double-blind, randomized, active control, 7-10days treatment for all subjects.

Conditions

  • Bacterial Infections

Interventions

  • Tedizolid (BAY119-2631)Drug

    50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days

  • Placebo Tedizolid (BAY119-2631)Drug

    50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days

  • LinezolidDrug

    50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days

  • Placebo LinezolidDrug

    50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Early Clinical Response at 48-72 Hours After the First Infusion of Study Drug in the ITT Analysis Set.Time frame: Baseline and 48-72 hours visit

Locations

55 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Chula Vista, California

  • Site not named

    La Mesa, California

  • Site not named

    Oceanside, California

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Teaneck, New Jersey

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Beijing, China

  • Site not named

    Chongqing, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Shanghai, China

  • Site not named

    Tianjin, China

  • Site not named

    Tianjin, China

  • Site not named

    Wuhu, Anhui, China

  • Site not named

    Fuzhou, Fujian, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Guangzhou, Guangdong, China

  • Site not named

    Wuhan, Hubei, China

  • Site not named

    Changsha, Hunan, China

  • Site not named

    Changsha, Hunan, China

  • Site not named

    Changsha, Hunan, China

  • Site not named

    Nanjing, Jiangsu, China

  • Site not named

    Nanjing, Jiangsu, China

  • Site not named

    Suzhou, Jiangsu, China

  • Site not named

    Wuxi, Jiangsu, China

  • Site not named

    Changchun, Jilin, China

  • Site not named

    Dalian, Liaoning, China

  • Site not named

    Shenyang, Liaoning, China

  • Site not named

    Shenyang, Liaoning, China

  • Site not named

    Xi'an, Shaanxi, China

  • Site not named

    Xi'an, Shaanxi, China

  • Site not named

    Jinan, Shandong, China

  • Site not named

    Taiyuan, Shanxi, China

  • Site not named

    Chengdu, Sichuan, China

Showing 40 of 55 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.